

Edit-R CRISPRa reagent platform, 12/17

December 2017—Horizon Discovery's Dharmacon announced the launch of its CRISPR activation reagent platform, the latest addition to the company's Edit-R portfolio for CRISPR-Cas⁹ genome engineering.

The Edit-R CRISPRa offering provides researchers interested in gain-of-function studies with a two-component system for drug discovery, disease modeling, or pathway analysis. It is available in lentiviral and synthetic formats and is well suited for robust overexpression in virtually any cell system. This format is also highly amenable to arrayed studies for high-throughput, complex phenotypic analysis.

[Horizon Discovery](#), +44 (0) 1223 976 000